A 6-Month, Multicenter, Randomized, Open Label, Parallel-group Study Comparing the Efficacy and Safety of a New Formulation of Insulin Glargine and Lantus Injected in the Morning or Evening in Patients with Type 1 Diabetes Mellitus with a 6-month Safety Extension Period
Adults with type 1 diabetes are invited to participate in a research study to compare the safety, effectiveness, & tolerability of new more concentrated form of insulin glargine with the currently marketed form known as Lantus® in adults with type 1 diabetes. There are 10 on-site study visits over an approximate 12 month period.
Julie Coffey at 319-353-6070 or firstname.lastname@example.org
Participants are invited to participate in a longitudinal study of brain changes in older adults. Participants include both male or female subjects from the ages of 55 to 90 years who are willing to participate in tests including brain imaging, blood sampling, spinal fluid testing, and memory testing over a four and a half year follow-up period. Qualified participants include four groups: healthy older adults with no memory problems, persons with mild memory problems, persons with moderate memory problems, and those with early Alzheimer’s disease. The study is conducted in cooperation with the Alzheimer’s Disease Neuroimaging Initiative supported by the National Institute of Health and the Alzheimer’s Association.
Participation is voluntary and compensation is provided.
Contact Karen Ekstam Smith at 319-353-5158
Participants in this research study have Small Cell Lung Cancer that has come back (disease has relapsed or there has been progression). The purpose of this research study is to evaluate how a drug called OSI-906 compares to Topotecan in trying to slow down the growth and/or progression of the tumors of patients with relapsed or recurrent Small Cell Lung Cancer. OSI-906 is an "investigational" anti-cancer agent, which means it has not yet been approved by the U.S. Food and Drug Administration (FDA) for use in patients with Small Cell Lung Cancer. Topotecan is an FDA approved drug for the treatment of patients with relapsed or recurrent Small Cell Lung Cancer. Approximately 10 people will take part in this treatment study conducted by investigators at the University of Iowa. About 95 people will take part in this treatment study at other cancer centers.
Cindy Robertson, 319-356-2778
Volunteers between the ages of 18 and 80 who have a diagnosis of bipolar disorder are invited to participate in a study at the University of Iowa. The study involves two visits of up to four hours each. Participants must be willing to undergo magnetic resonance imaging (MRI).
Compensation is provided.
This study is being conducted by the Department of Psychiatry.
Contact Lois Warren at 319-384-9379 or email@example.com
Participants in this research study have a higher risk myelodysplastic syndrome (MDS) or chronic myelomonocytic leukemia (CMML). This means that the participants' bone marrow does not create enough of at least one type of blood cell that their bodies need. The purpose of this research study is to compare the effects, good and/or bad on the MDS or CMML, of adding either the drug lenalidomide or the drug vorinostat to the regular treatment drug azacitidine. Participants in this study will be on one of the following treatment arms: azacitidine alone, azacitidine and lenalidomide or azacitidine and vorinostat. Participants only receive one of these study treatments. Azacitidine and lenalidomide are approved by the U.S. Food and Drug Administration (FDA) for the treatment of MDS, or one of its subtypes. The combination of azacitidine with the drug lenalidomide or with the drug vorinostat (as they are being used in this study) are both considered experimental, which means that they are not FDA approved for the treatment of MDS or CMML. Approximately 9 people will take part in this study conducted by investigators at the University of Iowa. Approximately 267 people will take part in this study nationwide.
Janan Geick-Miller, 319-356-3944
Copyright © 2013 The University of Iowa. All Rights Reserved.